Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 38 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

3%

1 trials in Phase 3/4

Results Transparency

11%

1 of 9 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

16Total
Not Applicable (10)
P 2 (5)
P 3 (1)

Trial Status

Unknown14
Recruiting14
Completed9
Withdrawn1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 9 completed trials

Clinical Trials (38)

Showing 20 of 20 trials
NCT04434040Phase 2Recruiting

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

NCT06495554Not ApplicableRecruiting

Danish Vulva Cancer Recurrence Study

NCT05027828Recruiting

CtDNA as a Novel Biomarker of Treatment Efficacy in Patients With Ovarian Cancer

NCT06707519Recruiting

NSCLC Liquid Biopsies and Exhaled VOC

NCT04457297Phase 3Completed

Initial Attack on Latent Metastasis Using TAS-102 for ct DNA Identified Colorectal Cancer Patients After Curative Resection

NCT04530890Not ApplicableRecruiting

Interest of Circulating Tumor DNA in Digestive and Gynecologic/Breast Cancer

NCT04966663Phase 2Recruiting

Using ctDNA to Determine Therapies for Lung Cancer

NCT05787197Recruiting

ctDNA in CRC Patients Undergoing Curative-intent Surgery for Liver Metastases

NCT06434896Not ApplicableRecruitingPrimary

Circulating Tumor DNA Based Adjuvant Chemotherapy in Stage II Colon Cancer Patients: the MEDOCC-CrEATE Trial

NCT05601505Phase 2Recruiting

Circulating Tumor DNA-guided Neoadjuvant Treatment Strategy for Locally Advanced Rectal Cancer

NCT05598528Recruiting

Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)

NCT06479460Recruiting

Clinical Application of ctDNA Dynamic Monitoring in Neoadjuvant Therapy for HER2-positive Breast Cancer Patients

NCT06404593Completed

Dynamic ctDNA Detection for Colorectal Cancer Liver Metastases

NCT05415787CompletedPrimary

Evaluation of the Technical Feasibility of Testing ct DNA for Homologous Recombination Gene Variants in Metastatic Prostate Cancer.

NCT05969938Unknown

Predicting the Efficacy and Prognosis of Rectal Cancer Patients Based on ctDNA-MRD Technology

NCT03737539Unknown

Dynamic Monitoring of ctDNA Methylation to Predict Relapse in Colorectal Cancer After Radical Resection (POSTCA)

NCT05801263Recruiting

ctDNA Methylation for Epithelial Ovarian Cancer

NCT05801276Recruiting

ctDNA Methylation for Detecting Ovarian Cancer

NCT03750175Completed

OPTImal PALliative Anti-epidermal Growth Factor Receptor Treatment in Metastatic Colorectal Cancer -

NCT04456972Not ApplicableCompletedPrimary

Reliability and Interest of Circulating Tumor DNA in Endometrial Cancers.

Scroll to load more

Research Network

Activity Timeline